All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Tumor-Informed ctDNA Assay May Aid Surveillance Strategies in Merkel Cell Carcinoma

August 5th 2024

A tumor-informed ctDNA assay showed high sensitivity and specificity as well as potential for ctDNA to be used as a prognostic biomarker during surveillance in Merkel cell carcinoma.

Suvemcitug Plus Chemo Boost PFS in Platinum-Resistant Ovarian Cancer

August 4th 2024

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib/Olaparib is Active in Recurrent, Platinum-Sensitive, Recurrent Ovarian Cancer Irrespective of HRD Status

August 3rd 2024

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

PGDx Elio Plasma Focus Dx Receives FDA De Novo Marketing Authorization for Pan–Solid Tumor Liquid Biopsy

August 2nd 2024

The FDA has granted de novo marketing authorization to the PGDx elio plasma focus Dx pan–solid tumor liquid biopsy test.

Refining Adjuvant Immunotherapy Use Is a Crucial Focus in Early-Stage NSCLC

August 2nd 2024

Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.

Bladder-Sparing Treatment Post–Pembrolizumab Progression Is Effective in BCG-Unresponsive NMIBC

August 2nd 2024

Roger Li, MD, discusses the efficacy of bladder-sparing therapy after progression on pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC.

BCMA/CD19–Targeting CAR T-Cell Therapy Is Effective in Newly Diagnosed Multiple Myeloma

August 2nd 2024

The BCMA/CD19–targeted CAR T-cell therapy GC012F was safe and produced favorable outcomes in newly diagnosed multiple myeloma after induction therapy.

New Research Discovers a New Combination of Therapy for People With a Type of Leukemia, Leading Them to Live Longer

August 2nd 2024

Researchers at the Mayo Clinic found that patients with BCP-ALL who lacked the Philadelphia chromosome and were in remission showed higher survival rates with blinatumomab plus chemotherapy.

Alemtuzumab Earns FDA Orphan Drug Designation for Lymphodepletion Before UCART22 in R/R B-ALL

August 2nd 2024

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

BTK Degraders and Fixed-Duration Regimens May Represent the Future in CLL

August 2nd 2024

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

FDA Grants Accelerated Approval to Afami-Cel for Advanced Synovial Sarcoma

August 2nd 2024

The FDA has granted accelerated approval to afamitresgene autoleucel for select patients with pretreated unresectable or metastatic synovial sarcoma.

FDA Awards Orphan Drug Designation to Avutometinib Plus Defactinib in Pancreatic Cancer

August 2nd 2024

The FDA granted an orphan drug designation to the combination of avutometinib and defactinib for use as a potential therapeutic option in patients with pancreatic cancer.

FDA Approves Expanded Indication for Dostarlimab Plus Chemo in Primary Advanced or Recurrent Endometrial Cancer

August 1st 2024

The FDA has approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or recurrent endometrial cancer.

ABBV-400 Demonstrates Preliminary Efficacy, Safety in MSS/pMMR Advanced CRC

August 1st 2024

ABBV-400 displayed efficacy and tolerability in microsatellite stable/mismatch repair–proficient advanced colorectal cancer.

EMA Grants Orphan Medicinal Product Designation to Rivoceranib/Camrelizumab in First-Line Unresectable HCC

August 1st 2024

The EMA has granted orphan medicinal product designation to rivoceranib plus camrelizumab in first-line unresectable hepatocellular carcinoma.

Teh Lin, Fox Chase Cancer Center Medical Physicist, Named Fellow of Prestigious Medical Association

August 1st 2024

Teh Lin, PhD, DABR, FAAPM, of Fox Chase Cancer Center, has been named a Fellow of the American Association of Physicists in Medicine.

FDA Grants Fast Track Designation to Soquelitinib for Relapsed/Refractory PTCL

August 1st 2024

Soquelitinib has received fast track designation from the FDA for patients with relapsed or refractory peripheral T-cell lymphoma after at least 2 lines of systemic therapy.

IMM-1-104 Earns FDA Fast Track Designation for First-Line PDAC

August 1st 2024

The FDA granted fast track designation to IMM-1-104 for first-line pancreatic ductal adenocarcinoma.

Clinically Guided Cannabis Use Helps Mitigate Symptoms Experienced by Patients With Cancer

August 1st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, highlight the importance of personalized cannabis use in alleviating treatment-related symptoms.

Integrated 15-GEP and PRAME Classifier Shows Prognostic Accuracy in Uveal Melanoma

August 1st 2024

Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma.